Ensus sequence although thinking of all these things.Idrees et al. Theoretical Biology and Healthcare Modelling 2013, ten:24 http://tbiomed/content/10/1/Page 7 ofPhylogenetic analysisHCV E1 and E2 sequences from around the globe have been analyzed to establish their evolutionary relationships utilizing the CLC workbench. The phylogenetic evaluation function in the workbench was utilised to construct phylogenetic trees for E1 and E2 proteins using the neighbor-joining technique having a bootstrap value of 100.Future directionsIn future, we aim to analyze these peptides further to indicate techniques for blocking HCV entrypeting interests The authors declare that they have no competing interests. Authors’ contributions UAA created the study, SI performed the sequence evaluation, NI helped in manuscript writing. All authors read and approved the final manuscript. Author facts 1 Division of Bioinformatics and Biotechnology, Government College University (GCU), Faisalabad, Pakistan. 2 Division of Food Sciences, Government College University (GCU), Faisalabad, Pakistan.921619-89-8 Purity Received: 29 January 2013 Accepted: 7 April 2013 Published: 10 April 2013 References 1.4,5-Dimethoxyphthalonitrile web Schaefer EAK, Chung RT: Anti-Hepatitis C Virus Drugs in Improvement. Gastroenterology 2012, 142:1340?350. two. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S: An overview of HCV molecular biology, replication and immune responses. Virol J 2011, 8:161. 3. Idrees M, Riazuddin S: Frequency distribution of hepatitis C virus genotypes in various geographical regions of Pakistan and their doable routes of transmission. BMC Infect Dis 2008, eight:69. 4. Idrees S, Ashfaq UA: A brief overview on dengue molecular virology, diagnosis, remedy and prevalence in Pakistan.PMID:23795974 Genet Vaccines Ther 2012, 10:6. 5. Idrees S, Ashfaq UA: RNAi: antiviral therapy against dengue virus. Asian Pac J Trop Biomed 2013, three:232?36. six. Higginbottom A, Quinn ER, Kuo CC, Flint M, Wilson LH, Bianchi E, Nicosia A, Monk PN, McKeating JA, Levy S: Identification of amino acid residues in CD81 essential for interaction with hepatitis C virus envelope glycoprotein E2. J Virol 2000, 74:3642?649. 7. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, Dong C, Weiner AJ, Lau JY, Choo QL, et al: A quantitative test to estimate neutralizing antibodies towards the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein two binding to target cells. Proc Natl Acad Sci U S A 1996, 93:1759?763. eight. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A: The human scavenger receptor class B sort I is actually a novel candidate receptor for the hepatitis C virus. EMBO J 2002, 21:5017?025. 9. Mazzocca A, Sciammetta SC, Carloni V, Cosmi L, Annunziato F, Harada T, Abrignani S, Pinzani M: Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem 2005, 280:11329?1339. 10. Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC: L-SIGN (CD 209 L) can be a liverspecific capture receptor for hepatitis C virus. Proc Natl Acad Sci U S A 2003, one hundred:4498?503. 11. Ashfaq UA, Masoud MS, Khaliq S, Nawaz Z, Riazuddin S: Inhibition of hepatitis C virus 3a genotype entry via Glanthus Nivalis Agglutinin. Virol J 2011, 8:248. 12. Ashfaq UA, Qasim M, Yousaf MZ, Awan MT, Jahan S: Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies. J Transl Med 2011, 9:194.doi:10.1186/1742-4682-10-24 Cite this arti.